Prognosis
Astra’s Pain Grows as U.S. Questions Beleaguered Vaccine
- U.S. panel raised issues with data hours after publication
- Drugmaker wants to update findings within the next 48 hours
This article is for subscribers only.
After enduring months of public criticism, AstraZeneca Plc finally caught a moment of reprieve for its Covid-19 vaccine this week when U.S. trial data showed the shot to be highly effective, working well in the elderly, and raising no safety concerns.
The good news lasted less than a day.